21:18 , Jun 21, 2019 |  BioCentury  |  Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

While Advent France Biotechnology and Medicxi are taking a wait-and-see approach with Yukin's kinase inhibitors targeting the NIK protein for cancer, the firms believe they could follow the biotech's €3.3 million ($3.7 million) seed round...
08:39 , Apr 3, 2019 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...
19:42 , Apr 21, 2017 |  BioCentury  |  Finance

Sowing French seeds

With the largest tech transfer fund in the country, Advent France Biotechnology is aiming to apply the academic IP commercialization model on a much larger scale than has previously been done in France. On April...
13:05 , Apr 20, 2017 |  BC Extra  |  Financial News

Advent France raising life sciences seed fund

Advent France Biotechnology announced the €64.8 million ($68.9 million) first close of its first life sciences seed fund. The firm plans to form and invest in companies based on IP out of several yet-to-be-disclosed French...